Details of the Drug
General Information of Drug (ID: DMOUPNT)
Drug Name |
1-(4-chlorobenzyl)-1H-indole-2,3-dione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
1-(4-Chlorobenzyl)-1H-indole-2,3-dione; 26960-66-7; 1-(4-chloro-benzyl)-1h-indole-2,3-dione; 1-(4-Chlorobenzyl)indoline-2,3-dione; NSC127077; 1-[(4-chlorophenyl)methyl]-2,3-dihydro-1H-indole-2,3-dione; 1-[(4-chlorophenyl)methyl]indole-2,3-dione; 1-[(4-chlorophenyl)methyl]benzo[d]azolidine-2,3-dione; 4-chlorobenzylisatin; NSC 127077; AC1Q3JHP; AC1Q3NUX; AC1Q3JHO; CBMicro_042181; AC1L5N5R; Isatin-based compound, 15; Cambridge id 6046772; 1-(4-chlorobenzyl)-isatin; CHEMBL376291; SCHEMBL3027106; BDBM22795; CTK4F8812; KS-00001RNX
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 271.7 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||